JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

JNJ

227.58

+1.12%↑

UNH

366.5

+3.49%↑

TMO

470.15

+0.34%↑

ISRG

466.67

-0.89%↓

ABT

93.81

+1.03%↑

Search

Heron Therapeutics Inc

Fermé

SecteurSoins de santé

1.21 2.54

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.19

Max

1.24

Chiffres clés

By Trading Economics

Revenu

15M

-3M

Ventes

2.4M

41M

BPA

-0.02

Marge bénéficiaire

-7.278

Employés

128

EBITDA

13M

-792K

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+278.15% upside

Dividendes

By Dow Jones

Prochains Résultats

11 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

6.2M

224M

Ouverture précédente

-1.33

Clôture précédente

1.21

Sentiment de l'Actualité

By Acuity

50%

50%

177 / 348 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bearish Evidence

Heron Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

28 avr. 2026, 23:33 UTC

Actions en Tendance

Stocks to Watch: Robinhood, Visa, Seagate Technology, NXP Semiconductors

28 avr. 2026, 23:24 UTC

Résultats

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20 Billion Buyback -- Update

28 avr. 2026, 23:15 UTC

Principaux Événements d'Actualité

U.K. Economy to Suffer Large Loss of Output, Higher Inflation as Result of Middle East Conflict

28 avr. 2026, 22:46 UTC

Résultats

Booking Holdings Cuts Outlook as Middle East Conflict Weighs on Travel Demand -- Update

28 avr. 2026, 22:37 UTC

Résultats

Prudential PLC 1Q New Business Profit $686.0 Million, Up 10% on Year

28 avr. 2026, 22:15 UTC

Résultats
Principaux Événements d'Actualité

Mondelez Reports Developing Market Growth Offsetting U.S., Europe Weakness -- Update

28 avr. 2026, 23:33 UTC

Market Talk
Principaux Événements d'Actualité

Gold Edges Lower on Prospects of Dollar Strength -- Market Talk

28 avr. 2026, 23:31 UTC

Résultats

China Petroleum & Chemical 1Q Net Rose on Higher Crude Oil Prices >0386.HK

28 avr. 2026, 23:31 UTC

Résultats

China Petroleum & Chemical 1Q Capex Was CNY25.17B >0386.HK

28 avr. 2026, 23:30 UTC

Résultats

China Petroleum & Chemical 1Q Net CNY17.74B Vs. Net CNY13.98B >0386.HK

28 avr. 2026, 23:30 UTC

Résultats

China Petroleum & Chemical 1Q Rev CNY706.70B Vs. CNY735.36B >0386.HK

28 avr. 2026, 23:19 UTC

Market Talk
Résultats

Visa Points to Spending Boost from Tax Refunds in U.S. -- Market Talk

28 avr. 2026, 23:09 UTC

Résultats

Visa 2Q Revenue Climbs as Consumers Keep Spending; Board Authorizes $20B Buyback -- Update

28 avr. 2026, 23:03 UTC

Market Talk

Australia's Inflation Outlook Looks Pretty Grim -- Market Talk

28 avr. 2026, 23:01 UTC

Principaux Événements d'Actualité

NIESR Sees One Rate Rise to 4% in Benign Scenario

28 avr. 2026, 23:01 UTC

Principaux Événements d'Actualité

NIESR Sees U.K. Economy Growing by Just 0.5% in 'Adverse' Middle East Scenario

28 avr. 2026, 23:01 UTC

Principaux Événements d'Actualité

NIESR: BOE's Key Rate Should Rise to 5.25% in Adverse Scenario

28 avr. 2026, 23:01 UTC

Principaux Événements d'Actualité

U.K.'s NIESR Lowers 2026 U.K. Economic Growth Forecast to 0.9% From 1.4% in 'Benign' Scenario

28 avr. 2026, 23:01 UTC

Principaux Événements d'Actualité

NIESR Sees Inflation Peaking at Over 6% in Adverse Scenario

28 avr. 2026, 22:51 UTC

Résultats

Robinhood Earnings Fall Short. A Crypto Slump Is the Culprit. -- Barrons.com

28 avr. 2026, 22:48 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28 avr. 2026, 22:48 UTC

Market Talk

Australia's 1Q CPI Will Likely Provide Little Relief For RBA -- Market Talk

28 avr. 2026, 22:40 UTC

Market Talk
Principaux Événements d'Actualité

Australian 1Q CPI Will Likely Keep May Hike Alive -- Market Talk

28 avr. 2026, 22:32 UTC

Résultats

Booking Beats on Profit. Travel Demand Outlook Clouded By Iran War. -- Barrons.com

28 avr. 2026, 22:25 UTC

Acquisitions, Fusions, Rachats

Pernod Ricard and Brown-Forman End Deal Talks -- Update

28 avr. 2026, 22:22 UTC

Résultats

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year

28 avr. 2026, 22:17 UTC

Market Talk

Canada Fiscal Update Puts Central Bank on Track to Raise Rates -- Market Talk

28 avr. 2026, 22:14 UTC

Résultats

Prudential PLC 1Q APE Sales Up 6% on Year, to $1.823B >2378.HK

28 avr. 2026, 22:14 UTC

Résultats

Prudential PLC 1Q New Business Profit $686.0M, Up 10% on Year >2378.HK

28 avr. 2026, 22:07 UTC

Market Talk
Principaux Événements d'Actualité

Canada Chamber Frets Over Lost Fiscal Room -- Market Talk

Comparaison

Variation de prix

Heron Therapeutics Inc prévision

Objectif de Prix

By TipRanks

278.15% hausse

Prévisions sur 12 Mois

Moyen 4.5 USD  278.15%

Haut 6 USD

Bas 3 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

2

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

2.0001 / 2.42Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

177 / 348Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Heron Therapeutics Inc

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.
help-icon Live chat